Enliven Therapeutics recasts FY2022 financials after reverse split; reports net loss of $37.7M

Enliven Therapeutics, Inc.

Annual meeting elected directors Heyman and Kintz; ratified Deloitte & Touche as auditor for FY2023.
Recasted FY2022 net loss of $37.7M ($12.05 per share) vs $24.7M in FY2021.
R&D expense rose 51% to $31.0M; G&A expense increased to $7.8M.
Cash and equivalents totaled $75.5M at Dec 31, 2022, down from $110.0M a year earlier.
Company expects current cash to fund operations for at least 12 months from March 2023.

item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Enliven Therapeutics, Inc. shareholders approved Election of two Class III Directors at the 2023-06-23 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-23

Exact text from the filing

Name of Director For Withheld Broker Non-Votes Richard Heyman, Ph.D. 30,518,067 385,508 1,641,388 Samuel Kintz, M.B.A. 30,900,278 3,297 1,641,388

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Enliven Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-23 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-23

Exact text from the filing

For Against Abstain 32,543,338 1,460 165

View on SEC.gov

Browse all shareholder votes →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-173796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.